A Phase 2 Open-Label Pilot Safety Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by IV Infusion Followed by Intratumoral Injection Prior to Standard Sorafenib Treatment in Patients With Unresectable Primary Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Pexastimogene devacirepvec (Primary) ; Pexastimogene devacirepvec (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Jennerex
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Jan 2015 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015 according to ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History